Business Context and Reporting Period
Company: Alpha Tau Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Date of Filing: July 21, 2026
Context: The filing discloses a press release regarding positive clinical trial data for the Company's Alpha DaRT® technology in combination with Pembrolizumab for treating locally advanced or metastatic head and neck cancer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on clinical trial results and does not contain financial statements or quarterly financial data.
Material Changes
Clinical Trial Results: The Company reported positive data demonstrating a 100% objective response rate and an 18.2-month median overall survival with Alpha DaRT® in combination with Pembrolizumab. These results surpassed the study's pre-specified threshold for success.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the successful achievement of clinical endpoints, suggesting potential regulatory or commercial advancement for the Alpha DaRT® platform in head and neck cancer.
Risks and Contingencies: The filing text does not explicitly detail new risks, contingencies, or unusual items beyond the standard legal disclaimer that the information is furnished and not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the attached press release (Exhibit 99.1) for detailed statistical analysis and study design specifics.
- Confirm the regulatory pathway and next steps following the achievement of the pre-specified success threshold.
- Review subsequent filings for any impact on the Company's cash burn rate or capital requirements resulting from this clinical milestone.
- Assess the competitive landscape for head and neck cancer treatments in light of the reported 100% objective response rate.